Tristel (TSTL) Share Price, News & Analysis

Company Overview

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes. Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries. The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL). For more information about Tristel's product range please visit: https://tristel.com

Key Stats

• Today's Range: 358.55 to 380
• 50-Day Range: 355.50 to 420
• 52-Week Range: 260 to 572.50
• Volume: 22,422 shs
• Average Volume: 98,151 shs
• Market Capitalization: £173.65 million
• P/E Ratio: 26.60
• Dividend Yield: 3.58%
• Price Target: GBX 400
• Consensus Rating: Hold

Tristel Stock Analysis - MarketRank™

Tristel scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Tristel has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Tristel has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Tristel is 26.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.63.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tristel is 26.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.12.

Price to Book Value per Share Ratio

Tristel has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TSTL.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Tristel is a leading dividend payer. It pays a dividend yield of 3.86%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Tristel does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Tristel is 95.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for TSTL.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for TSTL on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tristel insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.89% of the stock of Tristel is held by insiders.

Percentage Held by Institutions

50.37% of the stock of Tristel is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TSTL Stock Analysis - Frequently Asked Questions

How have TSTL shares performed this year?

Tristel's stock was trading at GBX 421.60 at the start of the year. Since then, TSTL shares have decreased by 13.8% and is now trading at GBX 363.50.

How were Tristel's earnings last quarter?

Tristel plc (LON:TSTL) released its earnings results on Monday, February, 24th. The company reported $8.17 earnings per share (EPS) for the quarter. Tristel had a trailing twelve-month return on equity of 20.43% and a net margin of 15.47%.

How do I buy shares of Tristel?

Shares of TSTL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Tristel own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tristel investors own include Standard Life Aberdeen (SL), Barclays (BARC), BP (BP), Capital One Financial (COF), Lloyds Banking Group (LLOY), Automatic Data Processing (ADP) and Ashtead Group (AHT).

Company Calendar

• Last Earnings: 2/24/2025
• Today: 8/25/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: N/A
• Current Symbol: LON:TSTL
• CIK: N/A
• Web: www.tristel.com
• Phone: +44-1638-721500
• Fax: N/A
• Employees: 208
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tristel: GBX 400
• High Price Target: GBX 400
• Low Price Target: GBX 400
• Potential Upside/Downside: +9.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 13.66
• Trailing P/E Ratio: 26.71
• Forward P/E Ratio: 22.40
• P/E Growth: N/A
• Net Income: £6.54 million
• Net Margins: 15.47%
• Pretax Margin: N/A
• Return on Equity: 20.43%
• Return on Assets: 9.89%

Debt

• Debt-to-Equity Ratio: 18.09
• Current Ratio: 3.75
• Quick Ratio: 3.83

Sales & Book Value

• Annual Sales: £42.24 million
• Price / Sales: 4.13
• Cash Flow: GBX 17.42 per share
• Price / Cash Flow: 20.96
• Book Value: GBX 68.34 per share
• Price / Book: 5.34

Miscellaneous

• Outstanding Shares: 47,770,446
• Free Float: N/A
• Market Cap: £174.36 million
• Optionable: Not Optionable
• Beta: 0.23